Alnylam Pharmaceuticals (ALNY) Announces Orphan Drug Status for ALN-TTR02
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) said the FDA has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam presents vutrisiran and zilebesiran data at ESC 2026
- Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
